---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-140533"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:37:47.139539+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa prices $100M public offering of common stock and pre-funded warrants

## Summary
- Priced 10.6M shares at $4.70/share and pre-funded warrants for 10.6M shares at $4.6999/warrant; gross proceeds $100M.
- Net proceeds ~$96.7M; expected close May 20, 2024; led by Dimension and a life-sciences institutional investor.
- Funds to advance MRT-6160, MRT-8102 clinical programs and QuEEN platform; cash runway into H1 2027.
- Underwriters: TD Cowen and Wedbush PacGrow.

## SEC filing metadata
- accession: 0001193125-24-140533
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312524140533/0001193125-24-140533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312524140533/d813909d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-140533
- JSON: https://secwatch.observer/filing/0001193125-24-140533.json
- Plain text: https://secwatch.observer/filing/0001193125-24-140533.txt

## Key facts
- Material Agreements
  Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, as representative of the several underwriters valued at approximately $96.7 million (effective 2024-05-15).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: TD Securities (USA) LLC, as representative of the several underwriters
  - Value: approximately $96.7 million
  - Effective: 2024-05-15
  source text: On May 15, 2024, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, as representative of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000119312524140533/0001193125-24-140533-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.